In support of our hypothesis, a recent trial provided initial evidence that a supervised exercise programme commencing two months after TKR resulted in improved function and reduced pain compared to a home exercise programme [ 35].
However, recent trials provide inconsistent results [ 4– 6, 18, 20].
Five randomised controlled trials of adjuvant treatment in patients with histologically proven pancreatic ductal adenocarcinoma were identified, of which the four most recent trials provided individual patient data (875 patients).
Over 30 patients have been treated worldwide using the current protocols, and recent trials provided the demonstration of long-term clinical efficacy of HSC gene therapy for SCID-ADA in combination with gene and cell therapy.
While recent clinical trials provide strong evidence that enhancing SERCA2a expression can alleviate impairment of cardiac function [ 48– 50], it remains unclear whether SERCA2a deficiency can itself precipitate decompensation and heart failure.
Recent results from a phase III trial provide additional evidence in favor of our conclusion [29].
Recent results from the American College of Surgeons Oncology Group Z0011 trial provide further evidence that SLNB is not inferior to ALND in women with one to two positive sentinel nodes when combined with current adjuvant radiotherapy and chemotherapy treatments (Giuliano et al, 2011).
Rather than confirm expected benefits, recent trials instead provide a most unwelcome quantification of the risks of intensive glycemic control, including high treatment costs, increased risk of severe hypoglycemia, substantial weight gain, and even, in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, an increased risk of death (4– 6).
A recent prospective clinical trial provides further evidence that breast cancers arising in germline BRCA1 mutation carriers are highly sensitive to cisplatin chemotherapy.
A recent randomized controlled trial provided compelling evidence that similar, and in some cases better, outcomes result if a restrictive transfusion strategy is maintained.
